Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
Title | Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis. |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Kallieri, M., Zervas E., Katsoulis K., Fouka E., Porpodis K., Samitas K., Papaioannou A. I., Kipourou M., Gaki E., Vittorakis S., Markatos M., Dimakou K., Ampelioti S., Koukidou S., Makris M., Ntakoula M., Mitrova M. Hadji, Glynos K., Antoniou K. M., Gaga M., Tzanakis N., Markopoulou K., Papakosta D., Bakakos P., & Loukides S. |
Journal | Int Arch Allergy Immunol |
Volume | 181 |
Issue | 8 |
Pagination | 613-617 |
Date Published | 2020 |
ISSN | 1423-0097 |
Abstract | INTRODUCTION: Mepolizumab is a monoclonal antibody against IL-5 for the treatment of severe eosinophilic asthma. The aim of the current study was to present a predesigned interim analysis of the data of patients who have completed 1 year of therapy with mepolizumab. |
DOI | 10.1159/000508559 |
Alternate Journal | Int Arch Allergy Immunol |
PubMed ID | 32570256 |